Drug intelligence / Profile preview

ZYSM004

Development stage: Preclinical
Lead developer: Yantai Rongchang Pharmaceutical
Modality: Small Molecules

Overview

ZYSM004 is a preclinical small molecule therapeutic candidate being developed by Rongchang Pharmaceuticals for the treatment of solid tumors. As part of the company's oncology pipeline, the specific biological target and mechanism of action for ZYSM004 remain undisclosed. The drug is currently in the early stages of development, specifically in the lead optimization or preclinical phase, aimed at identifying a viable candidate for clinical trials in various cancer indications.

Beyond the preview

Go deeper on ZYSM004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZYSM004.

Explore the full profile